Latest Biotech News

Regeneron won FDA accelerated approval for Otarmeni (lunsotogene parvec-cwha), positioned as the first in vivo gene therapy to restore neurosensory hearing for children and adults with...

Natera raised its 2026 revenue guidance after Q1 results showed a sharp acceleration across oncology and women’s health testing. The company increased full-year guidance to $2.74 billion to $2.82...

Bayer moved to expand its ophthalmology portfolio by acquiring Perfuse Therapeutics for $2.45 billion, gaining full rights to PER-001, a Phase II endothelin receptor antagonist for glaucoma and...

Researchers reported promising Phase II data for cancer of unknown primary (CUP) using a second-line regimen combining an anti–PD-1 immune checkpoint inhibitor with nab-paclitaxel. The study, led...

10x Genomics launched Atera, a new in situ spatial biology platform aimed at whole-transcriptome mapping with single-cell sensitivity at scale. The company said Atera is engineered to work across...

Caris Life Sciences submitted an application to the New York State Department of Health’s Clinical Laboratory Evaluation Program for authorization to perform Caris Assure in-state. The review will...

Odyssey Therapeutics completed an upsized IPO and concurrent private placement, raising $304 million to fund clinical-stage autoimmune and inflammatory pipeline development. The company priced...

Arrivent Biopharma received FDA IND clearance for ARR-002 (AV-P138-ADC), marking a step toward initiating a Phase I trial focused first on ovarian and endometrial cancers and expanding across...

ParcelBio raised $13 million in seed financing to build its APEXm platform for durable protein expression and to advance an in vivo CAR T program for autoimmune disease. The round was led by...

Pacific Biosciences trimmed the high end of its 2026 revenue guidance after lower-than-anticipated instrument demand and continued softness in academic funding, particularly in the Americas. The...

The FDA granted accelerated approval to Regeneron’s Otarmeni (lunsotogene parvec-cwha), positioning it as the first gene therapy designed to restore neurosensory function for OTOF-related...

Reports say Moderna has begun early-stage research into a hantavirus vaccine, a development that immediately moved investor expectations and reignited interest in unmet infectious-disease...

Guardant Health and Natera both reported quarter-strength diagnostics momentum tied to oncology testing—signals that continue to push liquid biopsy adoption beyond early-stage research. Guardant...

Researchers reported promising Phase II results for a second-line regimen in cancer of unknown primary (CUP), pairing an anti-PD-1 immune checkpoint inhibitor with nab-paclitaxel. The study frames...

Odyssey Therapeutics completed an upsized IPO and secured $304 million in gross proceeds to advance immunology-driven pipeline programs. The company priced 15.5 million shares at $18 each and...

Harbour Biomed received FDA IND clearance for HBM-7004, enabling first-in-human evaluation of the company’s B7H4 x CD3 bispecific antibody. The program is expected to start a Phase I trial in...

Caris Life Sciences filed an application with the New York State Department of Health for authorization to run its Caris Assure blood-based genomic profiling assay on specimens from New York. The...

10x Genomics sued Element Biosciences, alleging Element’s Aviti24 multiomic analysis platform infringes spatial technology patents licensed from Harvard University. The complaint was filed in US...

ParcelBio secured $13 million in seed financing to develop its Amplified and Prolonged EXpression mRNA (APEXm) platform and advance an in vivo CAR T program for autoimmune disease. The round was...

Seoul National University researchers published a next-generation CRISPR biocontainment technology intended to control engineered bacterial survival without DNA cleavage. The approach uses a...